BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $426,554 | +363.6% | 14,608 | +43.2% | 0.00% | – |
| Q2 2022 | $92,000 | -13.2% | 10,201 | -0.7% | 0.00% | – |
| Q1 2022 | $106,000 | -94.0% | 10,273 | -91.5% | 0.00% | -100.0% |
| Q4 2021 | $1,759,000 | -71.8% | 120,460 | -4.9% | 0.00% | -66.7% |
| Q3 2021 | $6,242,000 | +13.8% | 126,665 | +39.1% | 0.00% | 0.0% |
| Q2 2021 | $5,484,000 | +13.2% | 91,039 | +9.2% | 0.00% | 0.0% |
| Q1 2021 | $4,844,000 | +507.0% | 83,346 | +616.5% | 0.00% | +200.0% |
| Q4 2020 | $798,000 | +439.2% | 11,632 | +208.6% | 0.00% | – |
| Q3 2020 | $148,000 | -24.5% | 3,769 | -38.0% | 0.00% | – |
| Q2 2020 | $196,000 | +684.0% | 6,082 | +499.8% | 0.00% | – |
| Q1 2020 | $25,000 | -81.5% | 1,014 | -73.6% | 0.00% | – |
| Q4 2019 | $135,000 | +45.2% | 3,846 | -11.2% | 0.00% | – |
| Q3 2019 | $93,000 | -65.6% | 4,332 | -56.7% | 0.00% | – |
| Q2 2019 | $270,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |